CompanyNNVCNYSEShelton, CT

Nanoviricides, Inc.

Nanoviricides develops broad-spectrum antivirals using host-mimetic nanomedicine technology.

SEC EDGAR ClinicalTrials.gov nanoviricides.com

8-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

NanoViricides extends employment terms for President Diwan and CFO Vyas

Sep 29PeopleNanoviricides, Inc.

July 2026

NanoViricides closes $3.8 million offering, cuts ATM capacity to zero

Jul 30FinancingNanoviricides, Inc.

NanoViricides sets up at-the-market stock offering with D. Boral Capital

Jul 17PartnershipNanoviricides, Inc.

Nanoviricides files $4 million at-the-market stock offering with D. Boral Capital

Jul 17FinancingNanoviricides, Inc.